Faculty & Staff

· Abdel Aziz Shaheen
· Carla Coffin
· Cathy Lu
· Chris N. Andrews
· Christian Turbide
· Christopher Ma
· Cynthia H. Seow
· Gil Kaplan
· Henry Nguyen
· Humberto Jijon
· Joan Heatherington
· Jon Meddings
· Jose G.P. Ferraz
· Kelly Burak
· Kerri Novak
· Lawrence Price
· Lisa Douglas
· Maitreyi Raman
· Marie-Louise Martin
· Mark Swain
· Matthew Sadler
· Meredith Borman
· Paul James Belletrutti
· Paul L. Beck
· Puja Kumar
· Remo Panaccione
· Ronald Bridges
· Samuel Lee
· Sandra Anderson
· Stephen Congly
· Yasmin Nasser

Foothills Medical Centre

Remo Panaccione, MD, FRCPC

Professor of Medicine
Director, Inflammatory Bowel Disease Group

Administration Office:
Phone: 403-220-6166  Fax: 403-592-5050

Phone: 403-944-3267  Fax:

Curriculum Vitae

MD, University of Western Ontario; FRCPC


Clinical/Research Interests

Dr. Panaccione is an internationally recognized expert in inflammatory bowel disease (IBD) which consists of Crohn's disease (CD) and ulcerative colitis (UC). His special interest lies in the implementation and performance of clinical trials of new therapies in IBD. He also performs research in identifying new targets to develop new therapies in IBD. The University of Calgary IBD Clinical Trials Unit is ranked among the top five units in the world. In the last three years they have tested three new agents which have been approved for the treatment of IBD. The goal is to continue to develop therapies that will improve patient's quality of life and allow patients expanded choices.



1) Development of the paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process Peyrin-Biroulet L, Billioud V, D'Haens G, Panaccione R, Feagan B, Panés J, Danese S, Schreiber S, Ogata H, Hibi T, Higgins PD, Beaugerie L, Chowers Y, Louis E, Steinwurz F, Reinisch W, Rutgeerts P, Colombel JF, Travis S, Sandborn WJ. Am J Gastroenterol. 2012 Dec;107(12):1770-6. doi: 10.1038/ajg.2012.117. PMID: 23211844 [PubMed - in process] Related citations 2) Inflammatory bowel disease: a Canadian burden of illness review. Rocchi A, Benchimol EI, Bernstein CN, Bitton A, Feagan B, Panaccione R, Glasgow KW, Fernandes A, Ghosh S. Can J Gastroenterol. 2012 Nov;26(11):811-7. PMID: 23166905 [PubMed - in process] Related citations 3. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Kaplan GG, Seow CH, Ghosh S, Molodecky N, Rezaie A, Moran GW, Proulx MC, Hubbard J, Maclean A, Buie D, Panaccione R. Am J Gastroenterol. 2012 Dec;107(12):1879-87. doi: 10.1038/ajg.2012.333. Epub 2012 Nov 20. PMID: 23165448 [PubMed - in process] Related citations 4. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG; CERTIFI Study Group. N Engl J Med. 2012 Oct 18;367(16):1519-28. doi: 10.1056/NEJMoa1203572. PMID: 23075178 [PubMed - indexed for MEDLINE] Related citations 5. Development and validation of an administrative case definition for inflammatory bowel diseases. Rezaie A, Quan H, Fedorak RN, Panaccione R, Hilsden RJ. Can J Gastroenterol. 2012 Oct;26(10):711-7. PMID: 23061064 [PubMed - in process]

Referring Physicians